News › Clinical Practice, Industry News, Patient Care

FDA approves HA filler for midface via cannula injection

November 30, 2018

Galderma Laboratories announced in November 2018 that the FDA approved its hyaluronic acid dermal filler Restylane Lyft for correction of age-related midface deformities and cheek augmentation via a small blunt tip cannula.
One of the biggest debates in aesthetic medicine today is whether dermal fillers are best injected using cannulas or needles, according to Manhattan-based dermatologist Anne Chapas, M.D. Dr. Chapas was an investigator for the Galderma midface cannula study, which led to the FDA’s most recent approval for Restylane Lyft.
Read more at The Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Hims & Hers Plans Launch of Peptide Treatments Following Federal Policy Shift
    • FDA Requires New Safety Warning on GLP-1 Medications for Rare Eye Condition
    • Stella Advisory Becomes Silver Vendor Affiliate with the American Med Spa Association
    • Allergan Aesthetics Reports Aesthetic Treatment Satisfaction in Patients Using GLP-1s
    • Menopause and Aesthetics: What Medical Spas Need to Know About Skin Changes
Advertisement